ABLE

Multi-center, non-interventional study to collect data on the early use of ADSTILADRIN in a real-world setting.

A Phase 4, multi-center, open label trial to evaluate efficacy of retreatment (re-induction) with nadofaragene firadenovec (ADSTILADRIN) in subjects with carcinoma in situ (CIS) ± high-grade Ta/T1 and no complete response to first nadofaragene firadenovec dose.